Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy.

Wnt/β-catenin signaling pathway is one of the pathogenic mechanisms of glucocorticoid-induced osteoporosis (GIOP). We previously reported the potential of inhibiting sclerostin as a treatment for GIOP.